NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.386) was uploaded to the NHS England Website on Wednesday 11, February 2026.
The following changes have been introduced:
Durvalumab with gemcitabine and cisplatin (DUR8)
For neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Avelumab in combination with axitinib (AVE3)
For use in treatment-naïve patients with advanced, favourable risk, renal cell carcinoma where the following criteria have been met
Moved into routine commissioning - section B of list
Durvalumab (DUR7)
Durvalumab monotherapy for patients with limited- stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiotherapy where the following criteria have been met
Moved into routine commissioning - section B of list
Lorlatinib monotherapy (LOR2)
Lorlatinib monotherapy for anaplastic lymphoma kinase-positive advanced non- small cell lung cancer previously untreated with an ALK inhibitor where the following criteria have been met
Moved into routine commissioning - section B of list
Nivolumab (NIV25)
Nivolumab plus chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non- small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met
Date moving into routine commissioning updated
Abiraterone In combination with androgen deprivation therapy (ADT) (ABI4)
For the treatment of newly diagnosed high risk metastatic hormone-sensitive prostate cancer where the following criteria have been met
Treatment criterion (#6) updated
Bevacizumab with FIRST LINE fluoropyrimidine-based chemotherapy (BEV11)
For metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met
Treatment criterion (#4) updated
NA (NIV9)
NA
Treatment criterion (#8) updated
Pomalidomide (POM1)
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Treatment criterion (#6) updated
Belantamab mafodotin in combination with bortezomib and dexamethasone (BELA1)
Belantamab mafodotin in combination with bortezomib and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients who previously received lenalidomide as part of 1st line systemic therapy where the following criteria have been met
Spelling of drug name corrected to Belantamab mafodotin
Belantamab mafodotin with pomalidomide and dexamethasone (BELA2)
Belantamab mafodotin with pomalidomide and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients who previously received lenalidomide as part of 1st line systemic therapy where the following criteria have been met
Spelling of drug name corrected to Belantamab mafodotin